Biopharma & Life Sciences

CG Oncology Executive Compensation (FY25)

Name: CG Oncology (CGON) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

CGON · Executive and director compensation, fiscal 2023 to 2025

Chief executive, fiscal 2025

◇

Arthur Kuan

Median of the other named officers

$2,343,340

6 officers, excluding the chief executive

Latest say-on-pay support

June 4, 2026

Chief executive pay ratio

◇

To the median employee

Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.

See every company’s exec pay — free for 3 days, no card See the plan and pricing

The paid brief on CG Oncology

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$500 for the Executive Compensation Report. Both reports for $900.

Get the executive brief Get the board briefNo account needed.

Data as of November 5, 2026Latest filing (8-K): June 8, 2026

4 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

CG Oncology brief$500Get the executive brief

Velarion Intel, one year, every company

181 figures on this page: 180 cited to the filing that reported them, 1 calculated from figures it prints. See the citations

Frequently asked questions

Answers drawn from the data on this page.

Who is CG Oncology's chief executive and what were they paid?

Arthur Kuan, Chairman and Chief Executive Officer, received $11,928,401 in total compensation for fiscal 2025. Kuan's total was 6.8% higher than the $11,172,793 reported for fiscal 2024.

What was CG Oncology's say-on-pay result?

The say-on-pay proposal drew 97.6% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.

Which companies are in CG Oncology's peer group?

The disclosed peer group includes Agios, Akero, Arcellx, Arcus and Arrowhead, among others.

What is CG Oncology's chief executive pay ratio?

For fiscal 2025, the company reported a chief executive pay ratio of 39.6:1, against median employee compensation of $301,336.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Arthur Kuan Chief Executive Officer	◇	—	—	◇	◇	—	◇	◇
Ambaw Bellete President and Chief Operating Officer	◇	◇	—	◇	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Arthur Kuan Chief Executive Officer	◇	—	—	◇	◇	—	◇	◇
Prior Corleen Roche Chief Financial Officer	◇	◇	—	◇	◇	—	◇	◇
Ambaw Bellete President and Chief Operating Officer	◇	—	—	◇	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Arthur Kuan Chairman and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Ambaw Bellete President and Chief Operating Officer	◇	—	—	◇	◇	—	◇	◇
Vijay Kasturi Chief Medical Officer	◇	—	—	◇	◇	—	◇	◇
Joshua Patterson General Counsel, Chief Compliance Officer, and Secretary	◇	—	—	◇	◇	—	◇	◇
Corleen Roche Prior Chief Financial Officer	◇	—	—	◇	—	—	◇	◇
Robert Lapetina Prior Interim Principal Financial and Accounting Officer Served on an interim basis	◇	◇	—	◇	—	—	◇	◇
Jim DeTore Chief Financial Officer	◇	—	—	—	—	—	—	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Ambaw Bellete	OPTION	◇	—	—	◇	—	◇	◇
Arthur Kuan	PSU	◇	◇	◇	—	◇	—	◇
Arthur Kuan	OPTION	◇	—	—	◇	—	◇	◇
Corleen Roche	OPTION	◇	—	—	◇	—	◇	◇
Joshua F. Patterson	OPTION	◇	—	—	◇	—	◇	◇
Robert Lapetina	OPTION	◇	—	—	◇	—	◇	◇
Vijay Kasturi	OPTION	◇	—	—	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Arthur Kuan	Option	◇	—	◇	4/14/35
	Option	◇	—	◇	10/4/34
	Option	◇	—	◇	10/8/33
	PSU	◇	◇	—	—
	Option	◇	—	◇	10/18/32
	Option	◇	—	◇	12/12/33
Ambaw Bellete	Option	◇	—	◇	4/14/35
	Option	◇	—	◇	6/13/33
	Option	◇	—	◇	10/4/34
	Option	◇	—	◇	12/12/33
	Option	◇	—	◇	5/25/32
Vijay Kasturi	Option	◇	—	◇	8/14/33
	Option	◇	—	◇	4/14/35
	Option	◇	—	◇	10/3/34
	Option	◇	—	◇	12/12/33
Joshua Patterson	Option	◇	—	◇	4/14/35
	Option	◇	—	◇	5/14/34
	Option	◇	—	◇	10/3/34

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Arthur Kuan

Chairman and Chief Executive Officer · Terms as described in the company’s compensation discussion

Severance multiple	◇
Severance cash amount	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

Corleen Roche

Prior Chief Financial Officer · Terms as described in the company’s compensation discussion

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

Jim DeTore

Chief Financial Officer · Employment agreement

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-solicit period	◇

Joshua Patterson

General Counsel, Chief Compliance Officer, and Secretary · Terms as described in the company’s compensation discussion

Severance multiple	◇
Severance cash amount	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Christina Rossi	◇	—	◇	—	—	—	◇
Leonard Post, Ph.D Lead independent director	◇	—	◇	—	—	—	◇
Susan Graf	◇	—	◇	—	—	—	◇
Simone Song	◇	—	◇	—	—	—	◇
Brian Liu, M.D	◇	—	◇	—	—	—	◇
Victor Tong Jr	◇	—	◇	—	—	—	◇
James J. Mulé, Ph.D	◇	—	◇	—	—	—	◇

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Lead independent director premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

Agios AGIO
Akero AKRO
Arcellx ACLX
Arcus RCUS
Arrowhead ARWR
Arvinas ARVN
Denali DNLI
Geron GERN
IDEAYA symbol not shown
ImmunityBio IBRX
Immunovant IMVT
Intellia NTLA
Iovance IOVA
Neumora NMRA
Syndax SNDX
Vera VERA

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	June 4, 2026	=	◇	◇	◇

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Median employee compensation

◇

Chief executive total compensation

◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Arthur Kuan (Chairman and Chief Executive Officer), FY2025 total compensation $11,928,401 (base salary $690,000) [exec_comp, SEC accession 0001193125-26-177395, filed 2026-04-24]

See a complete sample report

What this page does not include

Everything above is a fact CG Oncology disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where CG Oncology sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $500

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

181 figures on this page: 180 cited to the filing that reported them, 1 calculated from figures it prints.

180 cited to the filing

1 calculated from the filing

Documents cited

8-K, filed June 8, 2026
0001193125-26-261670
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 24, 2026
0001193125-26-177395
CEO Pay Ratio · Compensation Discussion and Analysis
Filing, filed April 13, 2026
0001193125-26-152044
EX-10.1
DEF 14A, filed March 26, 2024
0000950170-24-036143
Fiscal Year 2024 Summary Compensation Table

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “CG Oncology executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/CGON (accessed 2026).

Short form: data: Velarion

The paid brief for CG Oncology

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$500 for the Executive Compensation Report. Both reports for $900.

Get the executive brief Get the board briefNo account needed.

4 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/CGON/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="CG Oncology executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about CG Oncology and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life Sciences CEO pay ratio — Biopharma & Life Sciences Say-on-pay support — Biopharma & Life Sciences

Peers CG Oncology discloses

The companies named in CGON's own disclosed peer group.

Agios Akero Arcellx Arcus Arrowhead Arvinas Denali Geron ImmunityBio Immunovant Intellia Iovance Neumora Syndax Vera

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on CG Oncology

Frequently asked questions

Executive compensation

Equity awards granted

Outstanding awards

Severance and change in control

Director compensation

Director fee schedule

Disclosed peer group

Say-on-pay history

Chief executive pay ratio

What this page does not include

Citations

Documents cited

The paid brief for CG Oncology

Biopharma & Life Sciences rankings

Peers CG Oncology discloses

Terms on this page